Marilyn Kwan to Protein Kinase Inhibitors
This is a "connection" page, showing publications Marilyn Kwan has written about Protein Kinase Inhibitors.
Connection Strength
0.232
-
Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov; 208(2):223-235.
Score: 0.232